Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis-Genentech’s DME drug Lucentis gets approval in Japan
Novartis and Genentech have jointly developed Lucentis, which is claimed to be the first anti-VEGF therapy approved for DME in Japan. Genentech has the commercial rights of the
Novartis and Genentech have jointly developed Lucentis, which is claimed to be the first anti-VEGF therapy approved for DME in Japan. Genentech has the commercial rights of the
EjectDelay is an US Food and Drug Administration (FDA) and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation. According
Vokanamet is a fixed-dose therapy combining canagliflozin and immediate release metformin in a single tablet. Canagliflozin, a member of a new class of drugs known as sodium glucose
Treatment will be carried out in CF patients aged six and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The MHRA has agreed to act as the Reference Member State for this Decentralised Procedure, which will include the UK, Denmark and Sweden. Elvanse is the first long-acting
The CHMP’s recommendation is now referred to the European Commission (EC) and if approved, the company will receive marketing authorization for Vimizim in all EU Member States. The
CVac is a personalized immunocellular therapeutic product and is currently under investigation for the treatment of epithelial ovarian cancer. The drug is intended to stimulate the immune system
The main aim of the deal is to increase the volume of clinical trials carried out in Germany, improve access to commercial clinical research for patients, accelerate the
Preeclampsia is one of the most common medical complications of pregnancy, and if left untreated it can progress to eclampsia, the life-threatening occurrence of seizures during pregnancy. It
The COAST (Patients with Stage IV COlorectal Cancer treated with Adjuvant Regorafenib Versus Placebo after Curative Treatment of Liver Metastases in A Randomized, Double-blind, Placebo-controlled Phase-III Study) clinical